【Product for Licensing】A Highly Differentiated B7-H3 x PSMA Bispecific ADC, Potentially Best-in-Class, for the Treatment of mCRPC

As present, prostate cancer is the most prevalent cancer type among men globally. As patients advance to castration-resistant prostate cancer (CRPC), treatment options become severely limited. This underscores a significant unmet clinical demand in metastatic castration-resistant prostate cancer (mCRPC). B7-H3 and PSMA, which are highly expressed in prostate cancer, are tumor-associated antigens. An emerging therapeutic strategy involves targeting both antigens with a dual-target antibody-drug conjugate (ADC), which has the potential to treat mCRPC.

The candidate is an innovative bispecific ADC that targets both B7-H3 and PSMA. It is composed of a bispecific antibody directed against B7-H3 and PSMA, a stable yet cleavable linker, and a potent topoisomerase 1 inhibitor as the payload.

Currently in preclinical research, the candidate has shown promising results as a novel prostate cancer treatment. In xenograft (CDX) models of human prostate cancer, it has effectively induced tumor regression in tumors with varying B7-H3 and PSMA expression levels. Compared to other competitors like DS-7300 and ARX517, the candidate has demonstrated superior antitumor efficacy. Moreover, the candidate has exhibited favorable pharmacokinetic properties and good tolerability.

To summarize, the candidate has competitive advantages: (1) Effective for all-comers of mCRPC; (2) Superior anti-tumor activity vs. single-target ADCs; (3) Overcoming tumor heterogeneity & drug resistance; (4) Lower off-target toxicity due to a stable linker.

If you are interested in this candidate, please contact DrugTimes BD Team at BD@drugtimes.cn.

Thank you very much!